2009-2014: PhD in Biomedical Science, East China Normal University (Shanghai Key Laboratory)
2003-2007: Bachelor in Biotechnology, Hefei University of Technology
2021.12-present: Researcher, East China Normal University (Shanghai Key Laboratory)
2018.8-2021.8: Assistant Researcher, Mayo Medical Center (USA Top1 Hospital)
2015.4-2018.8: Postdoctoral Researcher, Mayo Medical Center (USA Top1 Hospital)
2007.9-2008.7: Volunteer Teacher, College Student Western Program
2022: First Class Prize for Scientific and Technological Progress by the Ministry of Education
2022: Shanghai Pujiang Talent
2022: Zijiang Young Scholar
2018-2020: Mayo Edward C. Kendall Award in Biochemistry ($220,000)
Research
Development of anti-tumor drugs and drug resistance mechanisms Development of new diagnostic imaging agents for tumors Development of new drugs for anti-skin aging and promoting collagen synthesis
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside, Bao X*, Liang Y, Chang H, CaiT, Feng B, Gordon K, Zhu Y, Shi H, He Y *, Xie L*, 2024
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials, He Y, Xu W, Xiao Y, Huang H, Gu D, Ren S, 2022
FOXA1 overexpression inhibits interferon signaling and immune response in cancer, He Y, Wang L, Wei T, Su H, Hollern D, Ma J, Wen S, Xie H, Yan Y, Pan Y, Tang X, Suman V, Carter J, Weinshilboum R, Wang L, Kalari K, Boughey J, Dong H, Ye D, Perou C, Goetz M, Ren S and Huang H, 2021
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer, He Y, Wei T, Lin D, Fazli L, Karnes R, Jimenez R, Wang L, Wang L, Gleave M, Wang Y and Huang H, 2021
Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer, He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M, Tindall DJ, Li B, Zhu R, Wang L, Huang H, 2018
LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation, He Y, Zhao Y, Wang L, Bohrer LR, Pan Y, Wang L, Huang H, 2017
Ailanthone targets p23 to overcome MDV-3100 resistance in castration-resistant prostate cancer, He Y, Peng S, Wang J, Chen H, Cong X, Chen A, Hu M, Qin M, Wu H, Gao S, Wang L, Wang X, Yi Z, Liu M, 2016
TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer, Blee A*, He Y*, Yang Y*, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H, 2018
Mutated SPOP E3 ligase promotes 17βHSD4 protein degradation and drives androgenesis and prostate cancer progression, Shi L*, Yan Y*, He Y*, Yan B, Pan Y, Orme J, Zhang J, Xu W, Pang J, Huang H, 2021
Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122, Cong X*, He Y*, Wu H*, Wang D, Liu Y, Shao T, Liu M, Yi Z, Zheng J, Peng S, Ding T, 2021
Polydatin suppresses ultraviolet B induced cyclooxygenase 2 expression in vitro and in vivo via reduced production of reactive oxygen species, He Y, Liu Y, Lin Q, Zhu J, Zhang Y, Wang L, Ren XL, Ye X, 2012
Identification, synthesis and photo-protection evaluation of aryl thiazole derivatives as a novel series of sunscreens, Li G*, He Y*, Zhou W, Wang P, Zhang Y, Tong W, Wu H, Liu M, Ye X, and Chen Y, 2014
Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer, Wen S, He Y, Wang L, Zhang J, Quan C, Niu Y, Huang H, 2020
Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O‘PROTAC): Effective Targeting of LEF1 and ERG, Shao J, Yan Y, Ding D, Wang D, He Y, Pan Y, Yan W, Kharbanda A, Li H, Huang H, 2021
SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition, Ma J, Shi Q, Cui G, Sheng H, Botuyan MV, Zhou Y, Yan Y, He Y, Wang L, Wang Y, Mer G, Ye D, Wang C, Huang H, 2021
Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression, Lin Q, He Y, Wang X, Zhang Y, Hu M, Guo W, He Y, Zhang T, Lai L, Sun Z, Yi Z Liu M, Chen Y, 2020
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation, Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H, 2017
Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain, Peng S, Wang J, Chen H, Hu P, He X, He Y, Wang M, Tang W, He Q, Wang Y, Xie J, Guo D, Ren S, Liu M, Qiu W, Yi Z, 2020
EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis, Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H, 2019
A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer, Wang J, Xing Y, Wang Y, He Y, Wang L, Peng S, Yang L, Xie J, Li X, Qiu W, Yi Z, Liu M, 2019
Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer, Y Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, He Y, Wang D, and Huang H, 2018
PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer, Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W, 2017
Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion, Yang Y, Blee AM, Wang D, An J, Pan Y, Yan Y, Ma T, He Y, Dugdale J, Hou X, Zhang J, Weroha SJ, Zhu WG, Wang YA, DePinho RA, Xu W, Huang H, 2017
Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer, Wu C, Jin X, Yang J, Yang Y, He Y, Ding L, Pan Y, Chen S, Jiang J, Huang H, 2016
PubAngioGen: a database and knowledge for angiogenesis and related diseases, Li P, Liu Y, Wang H, He Y, Wang X, He Y, Lv F, Chen H, Pang X, Liu M, Shi T, Yi Z, 2015
LG308, a Novel Synthetic Compound with Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity, Qin M, Peng S, Liu N, Hu M, He Y, Li G, Chen H, He Y, Chen A, Wang X, Liu M, Chen Y, Yi Z, 2015
Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer, Hu M, Peng S, He Y, Qin M, Cong X, Xing Y, Liu M, Yi Z, 2015
Hydrogen sulfide promotes wheat seed germination and alleviate oxidative damage against copper stress, Zhang H, Hu LY, Hu K, He
Area of Focus
Peptides | Biochemistry | Pharmaceuticals | Drug Development | Pdt | Cancer Research | Molecular Biology | Chemical Synthesis | Protein Engineering | Therapeutics
Area of Focus
Anticancer | Biomolecular | Drug Development | Protein Design | Synthesis | Molecular Biology | Structural Biology | Cancer Therapy | Pharmaceuticals | Biochemistry
